Involvement of IL-9 in the bronchial phenotype of patients with nasal polyposis

Tsicopoulos, Anne; Shimbara, Ayako; Nadaï, Patricia de; Aldewachi, Oday; Lamblin, C; Lassalle, Philippe; Walls, Andrew F.; Sénéchal, Stephanie; Levitt, Roy C.; Darras, J. A.; Hamid, Qutayba; Wallaert, B.

doi:10.1016/j.jaci.2003.12.009

Cited by 39 publications

(34 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IL-13 mRNA can be detected in lavaged inflammatory cells from asthmatic subjects (5,7). IL-9 mRNA has been detected in the lavage of asthmatic children (23) and in bronchial biopsy specimens of subjects with bronchial hyperresponsiveness and increased eosinophilic infiltrates (38). However, the lack of detection of IL-9 or IL-13 in the bronchial brushings of the present study supports the hypothesis that inflammatory cells were not the source of the major portion of mRNA.…”

Section: Discussioncontrasting

confidence: 71%

Expression of the proapoptotic protein Bax is reduced in bronchial mucous cells of asthmatic subjects

Schwalm

Stevens²,

Jiang³

et al. 2008

American Journal of Physiology-Lung Cellular and Molecular Phys

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 71%

Expression of the proapoptotic protein Bax is reduced in bronchial mucous cells of asthmatic subjects

Schwalm

Stevens²,

Jiang³

et al. 2008

American Journal of Physiology-Lung Cellular and Molecular Phys

View full text Add to dashboard Cite

show abstract

“…In comorbid nasal polyposis and asthma, increased numbers of bronchoalveolar lavage eosinophils and eosinophil peroxidasestaining cells has been reported in subjects with airway hyperresponsiveness, compared with those without such hyperresponsiveness, along with an increased expression of IL-5 and eotaxin [43]. Involvement of IL-9 has also been suggested [44]. Similarly, the current author's group has recently reported a more marked lower airway inflammation in patients with nasal polyps and asthma that required inhaled corticosteroids, compared with those either without asthma, or with asthma but without nasal polyps [45].…”

Section: Upper Airways Diseasesmentioning

confidence: 99%

Influence of comorbid conditions on asthma

Lp¹

2009

Eur Respir J

222

169

View full text Add to dashboard Cite

Various conditions such as rhinosinusitis, gastro-oesophageal reflux disease, psychological disturbances, chronic infections and obstructive sleep apnoea are often observed in asthmatic patients and may affect asthma control and outcomes. These comorbidities may change the asthma phenotype, be part of the same pathophysiological process, act as confounding factors in the diagnosis or assessment of control of asthma, and/or result from specific environmental exposures. The influences of these conditions on asthma are variable and for many of them still uncertain; nevertheless, they may alter asthma responses to current therapy. A systematic evaluation and an appropriate treatment of asthma-associated comorbid conditions should be part of asthma management, particularly for severe disease. With regard to clinical research, associated conditions may influence the results of trials and should be taken into account in the subjects' inclusion criteria and analysis of data.

show abstract

“…The patients assessed the severity of symptoms (nasal obstruction, rhinorrhea, itching, sneezing, and hyposmia) into the following categories: 0 for lack of symptoms, 1 for mild, 2 for moderate, and 3 for severe symptoms, as previously described [13]. The maximal nasal symptom score is 15.…”

Section: Symptomsmentioning

confidence: 99%

Eosinophil Chemokines and Clara Cell Protein 16 Production in Nasal Mucosa of Patients with Persistent Allergic Rhinitis

et al. 2017

View full text Add to dashboard Cite

Objective: Eotaxin-2 and regulated on activation normal T cell expressed and secreted (RANTES) are involved in the eosinophil trafficking in patients with persistent allergic rhinitis (PAR). Clara cell protein 16 (CC16) is an anti-inflammatory protein mainly produced by the epithelial non-ciliated Clara cells. The aim of this study was to investigate the production of CC16 and chemokines eotaxin-2 and RANTES in nasal mucosa of patients with PAR.Materials and Methods: Twenty-one PAR patients and 20 healthy participants were included. CC16, eotaxin-2, and RANTES concentrations were measured in nasal secretions. PAR patients were administered fluticasone furoate nasal spray (220 μg daily for 14 days). We performed nasal cytology, symptom score assessment, and inflammatory mediator detection before and after the therapy.Results: The level of CC16 in patients with PAR was lower than in the healthy subjects (p=0.023). The eosinophil counts and local concentrations of eotaxin-2 and RANTES were higher in patients with PAR in comparison with controls (p=0.008, p=0.001, p=0.031, respectively). We also found a negative correlation between the CC16 and eotaxin-2 levels in nasal secretions of PAR patients (r=−0.492, p=0.023). After corticosteroid therapy, the patients with PAR had lower nasal symptoms, eosinophil counts, eotaxin-2, and RANTES levels and higher levels of CC16 (p<0.001 for all parameters). Conclusion:Our results suggest the presence of a negative correlation in production of CC16 and eotaxin-2 in nasal mucosa of patients with PAR. Intranasal corticosteroids have a suppressive effect on mucosal eosinophilic inflammation and a stimulating effect on local CC16 production.Keywords: Allergic rhinitis, chemokines, eosinophils, glucocorticoids, inflammation mediators ÖZ Amaç: Eotaksin-2 ve RANTES (aktivasyonla regüle edilen, normal T hücresi ekspresyonu ve sekresyonu) persistan alerjik riniti (PAR) olan hastalarda eozinofil göçünde yer almaktadır. Clara hücresi protein 16 (CC16) çoğunlukla sil içermeyen epitelyal hücreler tarafından üretilirler. Bu çalışmanın amacı PAR hastalarının nazal mukozasında CC16 ve eotaksin-2 ve RANTES kemokinlerinin üretimini araştırmaktır. Gereç ve Yöntemler:Çalışmaya 21 PAR hastası ve 20 sağlıklı katılımcı dahil edildi. Nazal sekresyonlardaki CC16, eotaksin-2 ve RANTES seviyeleri ölçüldü. PAR hastalarına flutikazon furoat nazal sprey uygulandı (14 gün boyunca günlük 220 μg doz). Tedavi öncesi ve sonrasında, nazal sitoloji, semptom skoru değerlendirmesi ve inflamatuar mediyatör taraması yapıldı.Bulgular: CC16 seviyesi PAR hastalarında sağlıklı deneklere kıyasla daha düşük bulundu (p=0,023). Kontrollere göre, eozinofil sayıları ve lokal eotaksin-2 ve RANTES seviyeleri PAR hastalarında daha yüksekti (sırasıyla p=0,008, p=0,001, p=0,031). Ayrıca PAR hastalarının nazal sekresyonlarında CC16 ile eotaksin-2 düzeyleri arasında negatif bir korelasyon bulundu (r=-0,492, p=0,023). Kortikosteroid tedavisi sonrasında, PAR hastalarında daha düşük nazal semptomlar, eozinofil sayıları, eotaksin-...

show abstract

Involvement of IL-9 in the bronchial phenotype of patients with nasal polyposis

Cited by 39 publications

References 44 publications

Expression of the proapoptotic protein Bax is reduced in bronchial mucous cells of asthmatic subjects

Expression of the proapoptotic protein Bax is reduced in bronchial mucous cells of asthmatic subjects

Influence of comorbid conditions on asthma

Eosinophil Chemokines and Clara Cell Protein 16 Production in Nasal Mucosa of Patients with Persistent Allergic Rhinitis

Contact Info

Product

Resources

About